

Feature Review

Prediabetes remission to reduce the global burden of type 2 diabetes

Leontine Sandforth^{1,2,3}, Stephanie Kullmann^{1,2,3}, Arvid Sandforth^{1,2,3}, Andreas Fritsche^{1,2,3},
Reiner Jumpertz-von Schwartzberg^{1,2,3,4,5}, Norbert Stefan^{1,2,3}, and Andreas L. Birkenfeld^{1,2,3,6,*}

Prediabetes is a highly prevalent and increasingly common condition affecting a significant proportion of the global population. The heterogeneous nature of prediabetes presents a challenge in identifying individuals who particularly benefit from lifestyle or other therapeutic interventions aiming at preventing type 2 diabetes (T2D) and associated comorbidities. The phenotypic characteristics of individuals at risk for diabetes are associated with both specific risk profiles for progression and a differential potential to facilitate prediabetes remission and reduce the risk of future T2D. This review examines the current definition and global prevalence of prediabetes and evaluates the potential of prediabetes remission to reduce the alarming increase in the global burden of T2D.

Need for prevention of T2D

One major global target for noncommunicable diseases is to halt the increase in the prevalence of T2D among adults, keeping the prevalence at 2010 levels. Yet, the number of people with T2D has nearly quadrupled since 1980, and incidence continues to rise, faster in low- and middle-income than in high-income countries and communities. Regions expected to experience very large increases in incident T2D are Latin America and the Caribbean, North Africa, the Middle East, and Southeast Asia. It will therefore be crucial to understand regional differences in individuals at risk of T2D and to define more effective strategies to prevent this large wave of incident T2D and its complications in the future [1–5].

In general, there are many conditions that predispose patients to developing T2D. One of the strongest risk factors is obesity, but also sedentary lifestyle, genetic predisposition, and history of gestational diabetes [6]. Other, less well-defined risk factors include chronic stress, certain infections, and specific drugs, such as certain checkpoint inhibitors in the treatment of cancer [7,8]. The best-studied condition with a high risk of progression to T2D is prediabetes – a condition affecting a highly heterogeneous group. Here, we will focus mainly on its different phenotypes and global pathophysiological aspects and discuss recent advances in prediabetes remission as an effective strategy to prevent incident T2D and potential complications.

Definitions and global epidemiology of prediabetes

Health organizations have proposed different definitions of prediabetes [9]. The American Diabetes Association (ADA, Box 1), defines prediabetes by at least one of the following conditions: fasting plasma glucose (FPG) between 100 and 125 mg/dl (6.5–6.9 mmol/l) [impaired fasting glucose (IFG)], 2-h plasma glucose in a 75 g oral glucose tolerance test (OGTT) between 140 and 199 mg/dl (7.8–11.0 mmol/l) [impaired glucose tolerance (IGT)], and/or hemoglobin A1c (HbA1c) between 5.7% and 6.4% (39–47 mmol/mol). The World Health Organization (WHO) uses the term ‘intermediate hyperglycemia’ instead of ‘prediabetes’; one of its criteria is FPG between 110 and 125 mg/dl (6.1–6.9 mmol/l), without a reliable cut-off value of HbA1c as the WHO stresses the concept of

Highlights

Prediabetes remission to normal glucose regulation (NGR), in addition to standard weight loss, lowers type 2 diabetes (T2D) risk more than standard weight loss alone.

Remission of prediabetes to NGR should be considered in guidelines and recommendations for the delay and prevention of T2D.

Future studies will provide evidence whether or not prediabetes remission can protect against incident T2D-related comorbidities such as cardiovascular and/or chronic kidney disease (CKD).

¹Institute for Diabetes Research and Metabolic Diseases of Helmholtz Munich at the University of Tübingen, Tübingen, Germany

²Internal Medicine IV, Endocrinology, Diabetology, and Nephrology, University Hospital Tübingen, Tübingen, Germany

³German Center for Diabetes Research, Tübingen, Germany

⁴M3 Research Center, Malignom, Metabolome, Microbiome, 72076 Tübingen, Germany

⁵Cluster of Excellence EXC 2124 ‘Controlling Microbes to Fight Infections’ (CMFI), University of Tübingen, Tübingen, Germany

⁶Department of Diabetes, Life Sciences, and Medicine, Cardiovascular Medicine and Life Sciences, King’s College London, London, UK

*Correspondence:
andreas.birkenfeld@med.uni-tuebingen.de (A.L. Birkenfeld).

Box 1. Mentioned studies, guidelines, and organizations

ADA: American Diabetes Association: one of the world's largest diabetes associations, founded in 1939

CATAMERI study: Catanzaro Metabolic Risk Factors study: an observational study enrolling White individuals with at least one cardiometabolic risk factor

Da Qing study: Da Qing Diabetes Prevention Study: aimed at investigating the effect of dietary and exercise intervention, on T2D incidence in people with impaired glucose tolerance in a randomized manner, starting in 1986 and including 577 adults

DCCPG: Diabetes Canada Clinical Practice Guidelines

DIRECT: Diabetes Remission Clinical Trial: open-label, cluster-randomized trial including 306 individuals with T2D from Scotland and the Tyneside region of the UK, starting in 2014

DPP: Diabetes Prevention Program: a study conducted from 1996 to 2001 in the USA comparing lifestyle intervention, metformin, or placebo, including 3234 individuals without T2D

DPPOS: DPP Outcome Study: further follow-up of 2776 individuals from DPP from 2002 to 2014 with semi-annually lifestyle reinforcement in the original lifestyle intervention group and unmasked metformin treatment in the original metformin group

Finnish DPS: Finnish Diabetes Prevention Study: lifestyle intervention study in 523 individuals with impaired glucose tolerance, recruited between 1993 and 1998 in Finland

IDF: International Diabetes Federation: world's largest diabetes organization, founded in 1950

IDPP: Indian Diabetes Prevention Program: comparing lifestyle modification, metformin, lifestyle modification, and metformin combined, with control in 531 Asian Indians with impaired glucose tolerance, recruited between 2001 and 2002

NDPP: National Diabetes Prevention Program: lifestyle intervention program established by the Centers for Disease Control and Prevention (CDC) in the USA since 2010

NHANES: National Health and Nutrition Examination Survey: program of the National Center for Health Statistics for assessing health and nutritional status of adults and children in the USA, started in 1960

NICE: National Institute for Health Care Excellence: publishes guidelines for the use of health technologies, clinical practice, guidance on health promotion and social care services in the UK

PLIS: German Prediabetes Lifestyle Intervention Study: conducted in Germany from 2012 to 2016 with ongoing follow-up, designed to investigate the effect of different intensities of lifestyle intervention in individuals with prediabetes

POP-ABC: Pathobiology of Prediabetes in a Biracial Cohort: prospective evaluation of the natural history of impaired glucose regulation that enrolled 376 individuals between 2006 and 2009 in the USA

RISC Study: European Relationship between Insulin Sensitivity and Cardiovascular Disease Study: enrolled 801 participants from 13 European countries between 2002 and 2004

TÜF study: Tübingen Family Study for T2D: enrolled 2600 individuals with normal glucose tolerance and with or without family history of T2D cross-sectionally

Whitehall II study: British study that included 10 308 civil servants to investigate social and occupational influences on health and disease from 1985 to 1988

WHO: World Health Organization: agency for global public health established in 1948

YMCA DPP: Young Men's Christian Association (YMCA) Diabetes Prevention Program: 12-month lifestyle intervention program for individuals at risk for T2D provided by the Young Men's Christian Association

Glossary

Glucagon-like peptide 1 (GLP-1): peptide hormone produced in the ileum and colon that regulates blood glucose level and satiety, amongst other functions.

Major adverse cardiac events (MACE): including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

Major adverse renal events (MARE): proposed to include new onset of kidney injury [persistent albuminuria/proteinuria and/or decreasing glomerular filtration rate (GFR) $<60\text{ ml/min/1.73 m}^2$], persistent signs of worsening kidney disease, development of end-stage kidney disease with estimated GFR $<15\text{ ml/min/1.73 m}^2$ without or with initiation of kidney replacement therapy, and death from renal cause [138].

Metabolic dysfunction-associated steatotic liver disease (MASLD): steatotic liver disease associated with cardiometabolic risk factors without elevated alcohol consumption.

Metabolically healthy obesity (MHO): individuals with obesity with a relatively low risk for cardiometabolic abnormalities.

Raster scan optoacoustic mesoscopy (RSOM): a method used for microvascular structure assessment with a laser.

Reactive oxidative species (ROS): highly reactive chemicals formed from oxygen that can exert damaging effects.

Sodium-glucose cotransporter 2 (SGLT2): a protein of the renal proximal tubule that helps reabsorbing glucose.

metabolic diseases as a continuum. Both the Diabetes Canada Clinical Practice Guidelines (DCCPG) and the National Institute for Health and Care Excellence (NICE) are aligned with the WHO in its FPG thresholds, but add HbA1c levels between 6.0% and 6.4%. Overall, the

ADA proposes the lowest cut-off values for prediabetes, allowing for identification of at-risk individuals at an early stage [10].

Recent observations show the age-adjusted global prevalence of IGT to be at 9.1% (464 million people) and of IFG to be at 5.8% (298 million people) in 2021 based on WHO criteria in the International Diabetes Federation (IDF) Diabetes Atlas [11]. The global prevalence of IGT is projected to increase to 10.0% (638 million people) and IFG to 6.5% (414 million people) in 2045. Applying ADA criteria, the same estimate may be up to 60% higher¹. Until 2045, the largest relative growth in cases of IGT and IFG is projected to occur in low-income countries, with a 12% and 6.7% increase, respectively (WHO criteria) [11]. While the prevalence of IGT is currently highest in North America and Caribbean regions (13.1%) and lowest in Southeast Asia (4.5%), Southeast Asia had the highest age-adjusted prevalence of IFG (9.4%) in 2021, reflective of genetic and environmental differences (Figure 1) [12,13]. Importantly, race- and ethnicity-specific prevalences of prediabetes in the USA do not differ between persons of non-Hispanic Asian (37.3%), non-Hispanic Black (NHB) (39.2%), Hispanic (35.4%), or non-Hispanic White (NHW) (38.7%) ancestry. These data suggest that local environmental factors might overrule genetic background in an obesogenic environment.

In the USA, one-third of the population lives with prediabetes, as diagnosed by ADA cut-offs, with NHW men being least aware of their condition, followed by NHB, Hispanic, and Asian people. Overall, prediabetes prevalence shows a clear association with age, with prevalence increasing from 27.8% in 18–44 years olds to 48.8% in >65 years olds in the USA (ADA). Similar to the differing definitions by health organizations, prediabetes prevalence greatly depends on applied thresholds [14,15]. The regional prevalence of IFG differs markedly from IGT. This could either result from differing diagnostic tools, for example, sole measurements of fasting glucose instead of performance of whole OGTT, and/or reflect differential pathophysiological patterns and/or ethnicity. Sensitivity of HbA1c testing was 83% in NHB, while being only 20% in NHW in the National Health and Nutrition Examination Survey (NHANES) [16]. However, sensitivity of IFG testing was only around 50% in NHB. This is partly associated with differing prevalences: IFG rate in NHB was 18%, while elevated HbA1c rate was 29.8%.

Progression to T2D differs between regions, which is reflected by the distribution of known T2D genetic variants [17,18]. In Asian Indians, T2D occurs at an earlier age than in Caucasian Whites [19]. A decreasing beta-cell function seems to play a major role in Asian Indians with impaired glucose regulation, specifically with IFG and IGT [12]. The progression rate of IGT to T2D is higher in Asian Indians, with a cumulative incidence of 55.0% in 3 years (18.3% per year) compared with Chinese (11.3% per year), Finnish (6.0% per year) and, American individuals (11 per 100 person-years) [20–22]. Furthermore, the risk thresholds of anthropometric measures are lower in Asian people compared with Caucasian Whites, as the risk of T2D increases already at a body mass index (BMI) of >23 kg/m² and a waist circumference of 85 cm for men and 75–80 cm for women [23]. For a given BMI, Asian Indians have been found to have a higher central adiposity accompanied by insulin resistance [24]. Moreover, recent elegant studies provide evidence that South Asians differ from White Europeans in the adipose tissue physiology of weight gain. Accordingly, differences in adipocyte morphology are associated with greater adverse metabolic changes with weight gain in South Asians [25]. In Black African individuals with prediabetes or T2D, beta-cell failure without significant insulin resistance was more frequent than insulin resistance while the insulin resistant phenotype showed a higher T2D prevalence [26]. As body weight, being a key indicator of insulin resistance, is increasing in most countries, the prevalence of prediabetes is expected to rise even faster than T2D prevalence [11,27,28].

Sex-specific considerations

Prediabetes affects females and males differently at different stages of life. Yet, high-quality data are still rare. In the USA, more males [41.0 (37.3–44.8%)] than females [32.0 (28.9–35.2%)] have

(A) Impaired fasting glucose






Figure 1. Color-coded age-adjusted prevalence for impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and type 2 diabetes (T2D) in adults aged 20–79 years by International Diabetes Federation (IDF) region. Dark red: highest prevalence; dark green: lowest prevalence. (B) Based on data from Rooney *et al.* [11], (C) based on data from IDF Diabetes Atlas 2021¹. IFG was defined as fasting plasma glucose levels of 6.1 to 6.9 mmol/l (110–125 mg/dl). Figure created using BioRender.

(B) Impaired glucose tolerance



(C) Type 2 diabetes



Trends in Endocrinology & Metabolism

prediabetes; however females were more aware of living with prediabetes than males [29]. Moreover, females with prediabetes had a greater increase in metabolic syndrome severity and central adiposity compared with males over time, which may, together with elevated coronary heart disease risk factors and stronger endothelial dysfunction already in the prediabetic state, contribute to the higher risk for cardiovascular diseases (CVDs) in females with T2D in the USA [30–33].

By contrast, in India, a larger proportion of people with prediabetes has IFG or even isolated impaired fasting glucose (i-IFG), with more than 70% being female, while IGT is more frequent

among males than among females [34]. In a Chinese cohort, physical activity favored remission from prediabetes to normal glucose tolerance (NGT) in males, while in females, lower waist circumference seemed to be more important. Here, high 2-h glucose in men, as opposed to high fasting glucose levels in females, were associated with a high risk for the progression to T2D [35].

While males with prediabetes seem to be more susceptible to develop T2D at a younger age than females [36], in the Rotterdam Study, lifetime risk of progression to T2D after 45 years of age was higher in females than in males, which may be explained by a diverging vulnerability of females and males to the effects of obesity and ageing [37,38].

Taken together, our knowledge on ethnic- and race-specific as well as sex-specific differences in people at risk for diabetes is still incomplete; it is imperative to conduct further investigations aiming at a comprehensive understanding of risk differences for developing T2D and the means of preventing it. This will be crucial for meeting the demands of modern medicine.

Pathophysiology and natural history of prediabetes

Obesity

Once prediabetes develops, glucose homeostasis is already strongly, but partly still reversibly, dysregulated. Its pathophysiology seems to be to some extent specific to the individual at-risk condition, including BMI category, body composition, and genetic risk.

Elegant cross-sectional studies have examined persons with obesity with NGT, some of whom are classified as people with so-called **metabolically healthy obesity (MHO)** (see [Glossary](#)), compared with lean persons with normal glucose regulation (NGR [39,40]). People with metabolically unhealthy obesity with NGT are characterized by whole-body insulin resistance with skeletal muscle and hepatic insulin resistance, higher insulin secretion, and reduced insulin clearance rate, leading to an increase in basal insulin values of >100% [40]. In these people, visceral adipose tissue (VAT), hepatic and skeletal muscle fat content, *de novo* lipogenesis, and cholesterol- and saturated fatty acid-triglyceride secretion rates are higher compared with those of people who are healthy and normal weight. Since insulin secretion rate, and thus beta-cell function, is reduced (while insulin secretion is increased), this may indicate that insulin secretion reaches a plateau [39,41,42]. Interestingly, recent data show that insulin secretion remains elevated in persons with obesity compared with lean people, even when matched for insulin sensitivity in a cross-sectional setting [43]. However, these data remain to be corroborated in longitudinal trials.

Ethnicity-specific differences seem to contribute to the heterogeneity, with a faster reduction in beta-cell function in African Americans and increased hepatic lipid accumulation and muscle insulin resistance despite lower body weight in Asian Indians [44–46].

In order to unravel early mechanisms of insulin resistance, young, lean, sedentary individuals without prediabetes have been examined upon high-carbohydrate mixed meals [47]. From this group, insulin-resistant individuals showed post-prandial skeletal muscle insulin resistance, which led to higher hepatic *de novo* lipogenesis by redirecting glucose from muscle to liver, where glucose uptake is not insulin dependent, and consequently, these young lean insulin-resistant individuals had higher hepatic and circulating triglyceride levels, compared with insulin-sensitive individuals. Prediabetes in the context of overweight/obesity is in most cases associated with increased energy intake, possibly from saturated fat sources and monosaccharides, which can cause ectopic lipid storage in VAT and numerous other organs. *De novo* lipogenesis in the liver and low-grade inflammation in adipose tissue contribute to ectopic lipid storage [48–52], while the regional distribution of ectopic lipid disposition in the body is, to an important extent,

genetically determined [53,54]. Ectopically stored lipids, especially diacylglycerols and ceramides, can lead to hepatic insulin resistance together with an adipose tissue–liver crosstalk via FFA/acetyl-Co [55–57]. Free fatty acids (FFAs) from VAT can drain via the portal vein directly to the liver, possibly exposing it to high concentrations of FFAs and glycerol [58]. So far, the contribution of FFAs drained from VAT to the portal vein has not been quantified in a longitudinal manner after weight loss, while in cross-sectional studies, FFAs drained from VAT to the liver were quantitatively lower than FFA from subcutaneous white adipose tissue. High FFAs in the pancreatic circulation, which may stem from very-low-density lipoproteins (VLDL) secreted by the liver and/or dietary and adipose tissue-derived sources, may hamper beta-cell function by impairment of beta-cell gene transcription and elevation of oxidative stress via **reactive oxygen species (ROS)** [59–61].

A liver fat content above 1.85% is already associated with hepatic insulin resistance [55,62,63]. As a consequence, an elevated fasting hepatic glucose production can result in IFG. However, the absolute level of liver fat at which metabolic deterioration begins varies from person to person. Studies have shown that people with obesity but a rather healthy metabolic phenotype have a reduced prevalence of **metabolic dysfunction-associated steatotic liver disease (MASLD)** compared with those with an unhealthy metabolic phenotype [64].

In people with prediabetes and obesity, the prevalence of visceral obesity, MASLD, and both insulin resistance and relative insulin secretion failure is high [65]. This is often accompanied by three or more criteria of the metabolic syndrome, reflecting a high-risk phenotype to develop T2D and complications.

In people with prediabetes and normal weight, however, relative beta-cell dysfunction occurs frequently, while insulin resistance is only present in around one-third of individuals. Rates of visceral adiposity are relatively low and of MASLD even lower.

Still, these phenotypes do not necessarily reflect the development of overall prediabetes, but rather different pathophysiological subgroups and traits of prediabetes [66]. Interestingly, the relationship between mortality and BMI just before incident T2D has been found to be J-shaped, with the highest hazard ratio for all-cause mortality in the normal weight (18.5–22.4 kg/m²) and the obese (≥35.0 kg/m²) BMI category [67].

Progression from NGR to prediabetes

In the postabsorptive state, approximately two-thirds of glucose uptake is independent of insulin [68]. To avoid resulting hypoglycemia, an equilibrium between the rate of glucose uptake and endogenous glucose production is achieved, mainly by the liver. Thus, FPG is primarily determined by hepatic glucose production, further being adapted by glucagon secretion [69,70]. In the postprandial state, carbohydrates are absorbed into circulation, stimulating insulin secretion, together with the gastrointestinal incretin receptor hormones **glucagon-like peptide 1 (GLP-1)** and glucose-dependent insulinotropic polypeptide (GIP). Both high glucose and insulin levels suppress hepatic glucose production and stimulate glucose uptake into peripheral tissues, mainly skeletal muscle, leading to high glucose disposal and, ultimately, normoglycemia [71]. Recent studies have shown that elevation of 1-h plasma glucose (1-h PG) seems to precede IGT, thereby suggesting that 1-h PG may be employed as an early marker of impaired glucose metabolism [72].

Impaired glucose regulation

Changes in glucose homeostasis are a continuum, probably starting years before prediabetes is diagnosed (Figure 2). While numerous studies focused on the conversion from prediabetes




Figure 2. Natural history of the transition from normal glucose regulation (NGR) to prediabetes subtypes [isolated impaired fasting glucose (i-IFG), isolated impaired glucose tolerance (i-IGT), and impaired fasting glucose (IFG)/impaired glucose tolerance (IGT) combined] and remission of prediabetes to NGR due to lifestyle changes. Top: insulin sensitivity reflected by oral glucose tolerance test (OGTT)-derived indices [oral glucose insulin sensitivity (OGIS); insulin sensitivity index; Matsuda index] and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Center: insulin secretion, reflected by Homeostasis Model Assessment of Beta-cell Function (HOMA-B) and/or area under the curve (AUC)_{c-pep0–30}/AUC_{gluc0–30} as an index of glucose-stimulated insulin secretion levels during a 75-g OGTT. Bottom: beta-cell function reflected by insulin secretion relative to insulin sensitivity (adaptation index and disposition index) [127,139,140]. OGTT glucose: OGTT-derived glucose curves in NGR and in prediabetes, divided in i-IFG (green line), i-IGT (yellow line), and IFG + IGT (red line). Figure created using BioRender.

to T2D, few studies have focused on the transition from NGR to prediabetes (i.e., i-IFG, i-IGT, or both). In a study of Pima Indians who are at high risk of developing T2D, individuals who progressed to T2D had beta-cell dysfunction even before the plasma glucose level rose into the prediabetic range, and beta-cell dysfunction worsened with rising plasma glucose levels [73,74].

The POP-ABC (Pathobiology of Prediabetes in a Biracial Cohort) study has identified several risk factors for the development of prediabetes. These include higher age, male sex, higher BMI, waist-to-hip ratio (WHR), plasma glucose levels, impaired insulin secretion and beta-cell dysfunction, higher triglycerides, lower adiponectin, higher alanine aminotransferase (ALT) levels, and higher blood pressure, amongst others [75,76]. People who progressed from NGR to prediabetes had lower insulin sensitivity compared with non-progressors, as measured by the gold standard technique hyperinsulinemic-euglycemic clamp, and a steeper decrease of insulin sensitivity over the years [77,78].

i-IFG

People with i-IFG are characterized by an elevated FPG (>100 mg/dl according to ADA criteria), an exaggerated early rise in plasma glucose concentration following glucose ingestion, and a 2-h glucose level similar to NGT. Most data indicate that people with i-IFG are primarily characterized by adipose tissue and hepatic insulin resistance with normal muscle insulin sensitivity, resulting in increased hepatic glucose output and increased fasting glucose levels [68,79–81]. The reason for the ability of people with i-IFG to maintain NGR after a glucose challenge is that muscle glucose disposal is not or only slightly impaired. Additionally, only first phase, but not second phase insulin secretion is mildly impaired and glucagon suppression by glucose stimuli is reduced, which is not specific to i-IFG only [82–84]. By contrast, the role of gut-derived incretins in i-IFG is less well understood and clearly needs further study [85].

Natural history of i-IFG

In the Inter99 study [86], 5 years before the progression to i-IFG, beta-cell function was already significantly impaired in normoglycemic individuals. Yet, during the development of i-IFG, beta-cell function did not decline further, indicating that a decreasing insulin secretion ability is not a major feature in the early stages of fasting hyperglycemia. Instead, these longitudinal data suggest that a steady decline in hepatic, but not muscle, insulin sensitivity, causes the development of prediabetes. However, muscle insulin sensitivity was already low at baseline in people progressing to i-IFG. The prediabetic state, i-IFG, therefore appears to be caused by a low baseline beta-cell function in combination with a progressive decline in hepatic insulin sensitivity. Indeed, a family history of T2D was more common in the i-IFG cohort than in the NGT group, suggesting a genetic or epigenetic impact in the development of i-IFG.

i-IGT

When glucose tolerance during OGTT is impaired, insulin secretion is not sufficient to lower plasma glucose to normal values within the normal timeframe. A lower insulin sensitivity has been consistently demonstrated in individuals with i-IGT in comparison to those with NGT [87–89]. An impairment in insulin-stimulated whole-body glucose disposal, which is mainly determined by skeletal muscle glucose uptake, but further contributed to by adipose tissue and hepatic glucose output, was observed in all ethnic groups studied, including Pima Indians, Hispanics, and Japanese [87,89–92]. High FFA levels can induce muscle insulin resistance [93] and defects in muscle glycogen synthesis occur in insulin resistance and contribute to elevated glucose levels by increasing the hepatic energy burden already at early stages [47].

Natural History of i-IGT

In the transition from NGT to prediabetes to T2D, peripheral insulin resistance can first be compensated by an increased insulin secretion by pancreatic beta cells. When prediabetes occurs, beta cells reach a plateau of their insulin secretion capacity and fail to lower plasma glucose levels into the normal range. People with i-IGT exhibit impairments in early and late phases of insulin secretion as well as alpha-cell function with reduced glucagon suppression by glucose stimuli [83,84]. The role of gut-derived incretins in i-IGT is less well understood and requires further investigation [85]. Several studies have shown that in individuals with i-IGT or IFG/IGT, the modulation of insulin secretion by incretins is impaired, further contributing to the progression towards T2D [94,95].

Combined IFG and IGT

In cross-sectional studies, people with obesity and IFG/IGT, a phenotype also referred to as metabolically unhealthy obesity, have severe metabolic disturbances as a combination of the single attributes of people with i-IGT and i-IFG [39].

Analysis of the natural history shows that people developing IFG/IGT within 5 years from NGT are able to increase a previously low insulin secretion rate (either determined by fasting insulin levels or by insulin levels during the 75-g OGTT), while beta-cell function (evaluated as insulin secretion rate relative to insulin sensitivity) declines, and hepatic- as well as skeletal muscle insulin sensitivity, which are low already at baseline, further decline.

Interesting to note is that individuals who develop IFG/IGT have more characteristics in common with those who developed i-IFG than with those who developed i-IGT, both in terms of sex distribution and family history of diabetes [86].

Natural history of i-IFG and i-IGT

Observation of the natural history of i-IFG highlights that 5 years prior to the development of IGT, beta-cell function was already lower compared with that of people with NGT and further declined over time, while insulin sensitivity was lower already at baseline but did not decline further [86]. The progressive reduction in beta-cell function over time may therefore be secondary to the insulin resistance observed at baseline. Together, this leads to increased basal and post-challenge insulin levels, which initiate a vicious cycle of insulin resistance and glucose toxicity. Factors such as lower physical activity and/or food quality, but also genetic or epigenetic factors, such as *in utero* programming, may contribute to lower insulin sensitivity [96,97].

Taken together, both i-IFG and i-IGT are conditions with impaired insulin sensitivity, yet, the site of insulin resistance, namely liver versus muscle, seems to differ. In this regard, i-IFG is mainly characterized by impaired hepatic insulin sensitivity, while i-IGT is associated with low whole-body insulin sensitivity [86,87]. Also, while mild impairments of mainly the early phase of insulin secretion seem to characterize beta-cell function in i-IFG, both phases are impaired in i-IGT.

High 1-h PG level

Earlier interventions are more successful in reverting pathophysiological changes such as beta-cell dysfunction. Therefore, since many people with prediabetes will inevitably progress to T2D due to the substantial decline in insulin sensitivity and beta-cell function already present at the time of diagnosis, earlier identification of people at high risk is required. In the Botnia Prospective Study, people with NGT had a low risk of roughly 2% for developing T2D. By contrast, people with NGT and a 1-h PG >155 mg/dl (8.6 mmol/l) had a roughly fivefold higher risk (8.5%) for future T2D compared with people with NGT and a 1-h PG <155 mg/dl (1.3%) [98].


Individuals with high 1-h PG can meet IFG, IGT, or both criteria, and/or NGT, partly reflecting differing metabolic endotypes and risk stages [99–102]. People with IFG and high 1-h PG had a significantly increased risk (11.4%) for future T2D compared with people with IFG and low 1-h PG (1.8%). People with IGT and high 1-h PG had a significantly higher risk (14%) for future T2D compared with people with IGT and low 1-h PG level, in which the risk of developing diabetes is nearly absent.

The European Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study compared pathophysiological features of persons with NGT with low and high 1-h PG as well as IGT. They found that people with NGT and high 1-h PG had a larger waist circumference, higher BMI, lower insulin sensitivity, higher FPG, and higher insulin secretion than people with low 1-h PG. Compared with people with IGT, most glucose measurements of people with 1-h PG were in between NGT and IGT. Thus, people with NGT but high 1-h PG seem to be, both pathophysiological as well as risk-wise, in a state between NGT and IGT. Most people with IGT also have high 1-h PG and recent regression models of longitudinal examinations show that elevation of 1-h PG seems to precede elevation of 2-h PG [72]. This stratification therefore

holds the potential to identify people at risk earlier than with conventional measures, opening up the possibility to implement preventive strategies earlier and therefore likely more successfully [103–105]. This has recently been underscored by findings from the Catanzaro Metabolic Risk Factors (CATAMERI) study, where high 1-h PG reflected reduced insulin sensitivity accompanied by impaired beta-cell function and identified individuals with an unfavorable cardiometabolic risk profile [106]. Still, whether or not people with elevated 1-h PG have a higher chance for remission to NGR needs to be formally proven.

Tübingen Clusters of people at risk for diabetes

Prediabetes has been linked to coronary artery disease, CKD, and all-cause mortality [2,3,107,108]. Still, the individual risk profile and severity of the developed type of prediabetes is not fully understood. A novel classification derived from the Tübingen Family Study (TÜF) of people at risk for T2D (Tübingen Clusters) includes people with a history of prediabetes, of gestational diabetes mellitus, with family history of T2D, and/or a BMI > 27 kg/m² (Figure 3) [107,109]. Initial hierarchical data-driven clustering used specific variables for risk cluster assignment, including OGTT-based indices of insulin sensitivity (Matsuda-index) and insulin secretion [area under the curve (AUC)_{0–30}C-peptide/AUC_{0–30}glucose] as well as AUC_{0–120}glucose for glycemia. Furthermore, VAT and subcutaneous adipose tissue volume from magnetic resonance imaging (MRI) measurements, intrahepatic lipid content from ¹H-magnetic resonance spectroscopy (¹H-MRS), high-density lipid (HDL)-cholesterol and triglycerides, and a genome-wide polygenic risk score for the differentiation between genetically determined beta-cell dysfunction and acquired beta-cell dysfunction were applied. In order to facilitate cluster assignment in clinical settings, clustering was reproduced with easy-to-assess clinical proxy parameters in the Whitehall II cohort. Individuals were thus clustered according to differences in BMI, FPG, 2-h PG, fasting insulin, 2-h insulin, and HDL-cholesterol and triglyceride levels. Amongst those individuals, six risk clusters with distinct phenotypes have been identified. Clusters 1, 2, and 4 have been identified to be low-risk clusters for T2D or related complications. Clusters 3, 5, and 6, however, have been identified as high-risk clusters. Individuals from cluster 3 have rather low insulin secretion, but a high genetic risk of T2D, leading to a high risk for T2D and CVD. Individuals from cluster 5 have a high liver fat content and a high risk for CVD, CKD, and T2D. Finally, individuals from cluster 6



Trends in Endocrinology & Metabolism

Figure 3. Overview with six risk clusters of people at risk for diabetes. In people with prediabetes, six risk clusters have been identified. Low-risk clusters are 1, 2, and 4 and high-risk clusters are 3, 5, and 6. All clusters are shown with phenotypic (within schematic person) and complications profile. Figure adapted from [141]. Clusters can be assigned by using the app of the Institute for Diabetes Research and Metabolic Diseases Tübingenⁱⁱ. Abbreviation: CKD, chronic kidney disease.

are characterized by a high VAT volume. As opposed to the other high-risk clusters, however, they have an intermediate T2D risk but high CKD risk. This reduced T2D risk can likely be explained by a high capability to secrete insulin, which overcomes insulin resistance, yet exposes individuals to high intrinsic insulin concentrations.

Therapeutic considerations: current approaches

Prevention of T2D

Several major randomized controlled lifestyle intervention (LI) trials examining the prevention of T2D have been conducted, including the Diabetes Prevention Program (DPP), the Finnish Diabetes Prevention Study (DPS), the DaQing Diabetes Prevention Study (DQDPS), and the Indian Diabetes Prevention Program (IDPP) [20–22,110]. The DPP examined >3000 individuals with IFG and IGT without T2D. Individuals were randomized to 850 mg of orally taken metformin once daily or placebo or LI with an aim of 7% body weight loss and at least 150 min of physical activity per week. Participants were followed up semi-annually for 4 years. Even though both LI and metformin were effective in preventing T2D, the LI group showed the lowest diabetes progression rates and the strongest weight loss, with one case of T2D prevented per seven persons treated for 3 years [28]. The Finnish DPS showed comparable results upon LI both after 4 years of active intervention and until 3 years after intervention [111]. A 6-year LI could reduce cardiovascular and all-cause mortality and diabetes incidence in Chinese individuals, achieving significance after a follow-up period of 23 years [112]. The IDPP showed a lower relative risk reduction of 28.5% over a median follow-up period of nearly 3 years with no additional benefit of metformin treatment in Indian individuals [108,110]. A recent study in Chinese individuals, however, showed that the combination of LI and metformin was even more effective than LI alone in preventing the progression from prediabetes to T2D [113].

When comparing different LI studies, the German Prediabetes Lifestyle Intervention Study (PLIS) was the first to investigate the intensity of LI in high- and low-risk phenotypes as a first step to individualized therapy [114,115]. PLIS has been conducted as a multicenter study by the German Center for Diabetes Research in nine clinical centers in Germany in the years 2012 to 2016, with follow-up still ongoing. A high-risk phenotype was characterized by relative beta-cell dysfunction and/or insulin resistance combined with MASLD and assigned individuals had higher BMI and higher age than low risk individuals. Low-risk participants were randomized to control LI or conventional (DDP-like) LI, whereas high-risk individuals were randomized to conventional or intensified LI. No medical intervention was performed, thereby being an easy-to-introduce program in the clinical outpatient setting. Individuals at high risk benefitted more from intensified LI but could not surpass individuals at low risk with standard LI only in terms of remission to NGT [114]. Thus, individuals at high risk can achieve a stronger risk reduction by adhering to intensive LI than to less intensive LI, but cannot reduce the risk to similarly low levels as persons at low risk with a standard therapy. These data suggest that preventive interventions in people with prediabetes need to start as early as possible to have the strongest effect on the absolute risk of progressing to T2D. When the PLIS intervention was evaluated within the Tübingen Clusters, high-risk clusters 3 and 6 benefitted particularly, which was dependent on the change in liver fat content in cluster 5 [116]. These data suggest that the amount of liver fat content and the change during a preventive LI plays an important role in mediating the success of the preventive strategy in high-risk cluster 5.

Prevention studies have been able to show the effectiveness of LI in diabetes prevention. Thus, two community-based programs have been set up in the USA: Young Men's Christian Association (YMCA) Diabetes Prevention Program (DPP) and the National Diabetes Prevention Program (NDPP) [117,118]. Even though LIs do not achieve as much weight loss in the participants as medical interventions, they bring less harm with them and might be more cost effective [119]. Recent studies have shown that incretin-based therapies are effective in inducing weight loss

mediating the reversal to NGR in individuals with obesity and prediabetes [120,121]. Still, maintaining NGR seems to remain challenging, specifically in the off-treatment period. Furthermore, the amount of required weight loss seems to differ between individuals [122].

Prediabetes remission

In light of the fact that a prediabetes diagnosis already indicates the presence of significant pathophysiological alterations, such as insulin resistance and/or beta-cell dysfunction, as discussed earlier, it is crucial to reverse these changes as early as possible to safeguard beta-cell function early and sustainably and to reduce the sequelae of long-standing insulin resistance (i.e., organ damage).

Therefore, while the remission of prediabetes indicates that most of these pathophysiological alterations have been (at least temporarily) reversed, weight loss without reversion to NGR is not associated with the same risk reduction as weight loss in combination with reversion to NGR [123]. The term remission has been proposed in T2D for reverting glucose levels to non-diabetic ranges ($\text{HbA}_{1c} < 6.5\%$) by an ADA expert group [124]. In people with T2D, DiRECT allowed for in-depth mechanistic insight into remission of T2D. Here, the increase in insulin secretion plays a major role [125]. Interestingly, both first-phase and maximal insulin secretion were increased in individuals who returned from T2D to prediabetes or NGT ('diabetes responders'). DiRECT reported a reduction in hepatic and pancreatic fat content upon LI but no differences between responders and non-responders in the context of T2D remission [126]. In prediabetes, pioneering work from the DPP Outcome Study (DPPOS) was the first to describe the effect of returning 2-h plasma glucose or fasting plasma glucose levels in people with prediabetes to normal levels ($<140 \text{ mg/dl}$, $<7.8 \text{ mmol/l}$) or normal FPG ($<100 \text{ mg/dl}$, $<5.6 \text{ mmol/l}$) on the risk of developing T2D. T2D incidence remained 56% lower after 3 years in people who regressed at least once to normal 2-h glucose levels. Nevertheless, longitudinal mechanistic insight, as in DiRECT, was not provided by DPPOS. Moreover, people reverting to NGR in DPPOS lost nearly twice as much body weight during the DPP phase, compared with those not reverting to NGR. Therefore, the impact of weight loss compared with reaching NGR was not finally solved.

To close this gap in our understanding of prediabetes remission and to identify underlying mechanisms, these mechanisms were investigated in PLIS, as described earlier [114]. Deep phenotyping, including five-point OGTT, whole-body MRI to assess body fat distribution, and ^1H -MRS to assess liver fat content was conducted in all patients at baseline and at the end of the LI at 12 months. To understand pathophysiological mechanisms that drive weight loss-induced remission of prediabetes, in participants who achieved the weight loss goal of at least 5% body weight loss, those who returned to NGR ('responders') were defined, compared with those who stayed in the prediabetic range ('non-responders'). This was termed prediabetes remission, defined by normal FPG ($<100 \text{ mg/dl}$, $<5.6 \text{ mmol/l}$), NGT (2-h plasma glucose level $<140 \text{ mg/dl}$, $<7.8 \text{ mmol/l}$), and $\text{HbA}_{1c} < 39 \text{ mmol/mol}$ ($<5.7\%$), without glucose-lowering medication for at least 3 months, according to ADA criteria [127]. Responders and non-responders had similar BMI, fat mass, and WHR at baseline. Weight loss was similar between responders and non-responders and hepatic fat content and skeletal muscle fat mass were reduced in a comparable manner in both groups. Still, responders showed a stronger reduction of both WHR and VAT than non-responders. Stronger VAT reduction was associated with higher proportions of prediabetes remission in a 'dose-dependent' manner (i.e., the stronger the VAT loss, the higher the prediabetes remission rate). Improvement in insulin sensitivity as determined by OGTT-derived indices was stronger in responders than in non-responders (Figure 4, Key figure). These findings were validated in a comparable subgroup of DPP participants who lost at least 5% of the initial body weight. While insulin secretion did not change in both groups, beta-cell function increased numerically, but not significantly, in responders. Thus, the major driver of prediabetes remission seems to be insulin sensitivity, which is an important difference to remission of T2D. It seems to open a window of

opportunity to tackle metabolic disease at a time-point when beta cells are not yet severely and persistently damaged.

Importantly, in PLIS participants who returned to NGR, the risk of developing T2D within 3 years after study initiation was reduced by 73% (Figure 4). Urine albumin-to-creatinine ratio was lower in responders at 3 years after study initiation, possibly reflecting a lower risk for future nephropathy. Furthermore, **raster scan optoacoustic mesoscopy (RSOM)** as a measurement of epidermal small-vessel morphology revealed more junction-to-endpoint branches and dermis-vessel density, reflecting a better small-vessel integrity in responders compared with non-responders in a subgroup of PLIS participants after the intervention.

Weight loss and glycemic goals for the prevention of T2D

The presented data prompt the question of whether prediabetes remission is more effective than the currently recommended strategies for the prevention of T2D and its associated complications in the ADA Standards of Care for the prevention and delay of T2D [29]. Here, individuals with overweight and obesity and at risk of developing T2D are advised to lose a minimum of 7% of body weight.

Key figure

Weight loss induced prediabetes remission and related risk reduction through returning to normal glucose tolerance




Figure 4.

This notion is primarily based on findings from DPP and comparable studies. It was thus tested if guideline-based weight loss of $\geq 7\%$ with targeted prediabetes remission to NGR is more effective than the same weight loss without remission in individuals with prediabetes in DPPOS. Results indicate that weight loss and targeted prediabetes remission reduced the relative risk of developing T2D by 76% (absolute risk: -10.1%). It would be of high clinical relevance to determine if prediabetes remission to NGR in conjunction with guideline-recommended weight loss also reduces the incidence of complications compared with similar weight loss without remission [128]. Thus, not only weight loss, but also targeting NGR should be considered in the treatment of prediabetes to prevent T2D. To achieve this goal, additionally increasing physical exercise needs to be considered, as positive effects of exercise on reducing VAT have also been shown [127,129,130]. As weight loss is an effective and straightforward way to achieve prediabetes remission, a general aim of losing at least 7% body weight and further until the personal threshold of the return to NGR is reached has been proposed [122,131]. Given these data, prediabetes remission holds the potential to be more effective than current concepts in the global fight against the ever-increasing incidence of T2D. Prediabetes remission as a treatment target is a clear goal assessable on a global scale [103,123].

Concluding remarks and future perspectives

Prediabetes is a condition associated with heterogeneous complications. Some individuals with prediabetes are at elevated risk for complications such as CVD and CKD, even without the progression to T2D, and others have a high risk of developing overt T2D over the course of their lifetime [107]. The individual risk profile is associated with specific phenotypic characteristics such as high visceral and/or high liver fat, but also with brain insulin resistance, often in connection with a chronic inflammatory state. These phenotypic alterations may be influenced by lifestyle aspects such as nutrition and physical activity, but can partly be determined by genetic disposition. As peripheral and brain insulin resistance seem to influence each other, manipulation of brain insulin signaling has been shown to regulate and/or disrupt glucose and lipid metabolism in several peripheral tissues [132]. Upon LI, brain insulin sensitivity is a significant predictor for VAT loss and individuals with higher brain insulin sensitivity maintain this reduction for a longer period of time than brain insulin-resistant persons [133]. First evidence shows that brain insulin resistance can be overcome by physical exercise and pharmacological interventions, such as **sodium-glucose co-transporter 2 (SGLT2)** inhibition, making it an important target for future interventional strategies [134,135].

To reduce the risk of complications and T2D, targeted prediabetes remission or NGR together with guideline-based weight loss should be the primary therapeutic objective in the future [123]. Intervention programs, taking cultural and socio-economic factors into account, should be made broadly accessible. Depending on the individual phenotype and risk profile, specific therapeutic interventions could be considered, while low-risk individuals may benefit from close monitoring [136]. In this regard, it will be important to determine the precise responses of the Tübingen Clusters of people at risk for diabetes for preventive measures and therapeutic interventions. As weight loss remains the most effective strategy, different means to induce weight reduction are currently being investigated in these clusters [137]. Furthermore, knowledge is needed on how prediabetes remission impacts long-term outcomes such as **major adverse cardiovascular events (MACE)**, **major adverse renal events (MARE)**, cancer incidence, and mortality (see [Outstanding questions](#)). Finally, one of the most pressing questions is how ethnicity-related and cultural differences in the risk of T2D can be addressed by prediabetes remission to NGR and if and how prediabetes remission can be implemented in different parts of the world. Potentially, the 1-h PG threshold may help improve remission responses. In order to facilitate its implementation, it will be important to determine if a single, cheap, and readily available biomarker can be used in the future to ascertain that prediabetes remission was achieved. Current studies addressing this pressing question are ongoing.

Outstanding questions

Can we establish effective, population-specific predictive biomarkers for prediabetes remission in people of different ancestries?

How can population-specific differences in the risk of diabetes be addressed by deploying precision medicine?

How can preventive prediabetes remission strategies be implemented, also taking cultural and socio-economic factors into account?

Can prediabetes remission reduce long-term vascular, malignant, and neurodegenerative outcomes?

Does prediabetes remission have a 'legacy' (preventive) effect on future comorbidities?

Can prediabetes remission to normal glucose regulation be cost-effective to prevent T2D and its comorbidities?

Acknowledgments

We thank Hans-Ulrich Häring for establishing the Tübingen Family Study (TÜF) in 2002 without which many studies referenced here would not have been possible. A.L.B. is supported by grants from the German Research Association (BI1292/11-1, BI1292/13-1, GRK 2812), as well as funding via the German Center for Diabetes Research (DZD, 01GI0925) via the German Federal Ministry of Education and Research. L.S. is supported by the German Research Association as a Clinician Scientist.

Declaration of interests

No interests are declared.

Resources

ⁱwww.cdc.gov/diabetes/php/data-research/index.html

ⁱⁱ<https://diabetesatlas.org/atlas/tenth-edition/>

ⁱⁱⁱ<https://prediabclusters.idm-tuebingen.org>

References

- Chen, L. *et al.* (2012) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. *Nat. Rev. Endocrinol.* 8, 228–236
- Tabák, A.G. *et al.* (2012) Prediabetes: a high-risk state for diabetes development. *Lancet* 379, 2279–2290
- Schlesinger, S. *et al.* (2022) Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. *Diabetologia* 65, 275–285
- Sathish, T. (2023) Personalized lifestyle change approaches for preventing type 2 diabetes in people with prediabetes. *Int. J. Diabetes Dev. Ctries.* 43, 993–994
- Wareham, N.J. (2022) Personalised prevention of type 2 diabetes. *Diabetologia* 65, 1796–1803
- DeFronzo, R.A. *et al.* (2015) Type 2 diabetes mellitus. *Nat. Rev. Dis. Primers* 1, 1–22
- Leiter, A. *et al.* (2021) Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: beyond autoimmune insulin-dependent diabetes. *Diabetes Res. Clin. Pract.* 172, 108633
- Kouitcheu Mabeku, L.B. *et al.* (2020) *Helicobacter pylori* infection, a risk factor for type 2 diabetes mellitus: a hospital-based cross-sectional study among dyspeptic patients in Douala-Cameroon. *Sci. Rep.* 10, 12141
- Davidson, M.B. (2022) Historical review of the diagnosis of prediabetes/intermediate hyperglycemia: case for the international criteria. *Diabetes Res. Clin. Pract.* 185, 109219
- Lima, L.M.T.R. (2017) Prediabetes definitions and clinical outcomes. *Lancet Diabetes Endocrinol.* 5, 92–93
- Rooney, M.R. *et al.* (2023) Global prevalence of prediabetes. *Diabetes Care* 46, 1388–1394
- Stamez, L.R. *et al.* (2013) Evidence of reduced β -cell function in Asian Indians with mild dysglycemia. *Diabetes Care* 36, 2772–2778
- Weber, M.B. *et al.* (2016) The stepwise approach to diabetes prevention: results from the D-CLIP randomized controlled trial. *Diabetes Care* 39, 1760–1767
- Hostalek, U. (2019) Global epidemiology of prediabetes - present and future perspectives. *Clin. Diabetes Endocrinol.* 5, 5
- Echouffo-Tcheugui, J.B. and Selvin, E. (2021) Prediabetes and what it means: the epidemiological evidence. *Annu. Rev. Public Health* 42, 59–77
- Sentell, T.L. *et al.* (2012) Racial/ethnic variation in prevalence estimates for United States prediabetes under alternative 2010 American Diabetes Association Criteria: 1988–2008. *Ethn. Dis.* 22, 451–458
- Chen, R. *et al.* (2012) Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases. *PLoS Genet.* 8, e1002621
- Waters, K.M. *et al.* (2010) Consistent association of type 2 diabetes risk variants found in Europeans in diverse racial and ethnic groups. *PLoS Genet.* 6, e1001078
- Chiu, M. *et al.* (2011) Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. *Diabetes Care* 34, 1741–1748
- Tuomilehto, J. *et al.* (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N. Engl. J. Med.* 344, 1343–1350
- Pan, X.-R. *et al.* (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. *Diabetes Care* 20, 537–544
- Knowler, W.C. *et al.* (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* 346, 393–403
- Qiao, Q. and Nyamdorj, R. (2010) The optimal cutoff values and their performance of waist circumference and waist-to-hip ratio for diagnosing type II diabetes. *Eur. J. Clin. Nutr.* 64, 23–29
- Nowlin, S.Y. *et al.* (2016) Explaining racial/ethnic dietary patterns in relation to type 2 diabetes: an analysis of NHANES 2007–2012. *Ethn. Dis.* 26, 529–536
- McLaren, J. *et al.* (2024) Weight gain leads to greater adverse metabolic responses in South Asian compared with white European men: the GlasVEGAS study. *Nat. Metab.* 6, 1632–1645
- Ishimwe, M.C.S. *et al.* (2021) Beta-cell failure rather than insulin resistance is the major cause of abnormal glucose tolerance in Africans: insight from the Africans in America study. *BMJ Open Diabetes Res. Care* 9, e002447
- Andersson, T. *et al.* (2015) Diabetes prevalence in Sweden at present and projections for year 2050. *PLoS One* 10, e0143084
- Echouffo-Tcheugui, J.B. *et al.* (2023) Diagnosis and management of prediabetes: a review. *JAMA* 329, 1206–1216
- American Diabetes Association Professional Practice Committee (2023) Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes—2024. *Diabetes Care* 47, S43–S51
- Yoshida, Y. *et al.* (2022) Sex differences in the progression of metabolic risk factors in diabetes development. *JAMA Netw. Open* 5, e2222070
- Donahue, R.P. *et al.* (2007) Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women?: the Western New York Study. *Diabetes Care* 30, 354–359
- Haffner, S.M. *et al.* (1997) Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. *Diabetologia* 40, 711–717
- Kannel, W.B. and McGee, D.L. (1979) Diabetes and cardiovascular risk factors: the Framingham study. *Circulation* 59, 8–13
- Narayan, K.M.V. *et al.* (2024) Natural history of type 2 diabetes in Indians: time to progression. *Diabetes Care* 47, 858–863
- Song, X. *et al.* (2016) Gender-related affecting factors of prediabetes on its 10-year outcome. *BMJ Open Diabetes Res. Care* 4, e000169
- Ligthart, S. *et al.* (2016) Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to

- type 2 diabetes: a prospective cohort study. *Lancet Diabetes Endocrinol.* 4, 44–51
37. van Herpt, T.T.W. *et al.* (2020) Lifetime risk to progress from pre-diabetes to type 2 diabetes among women and men: comparison between American Diabetes Association and World Health Organization diagnostic criteria. *BMJ Open Diabetes Res. Care* 8, e001529
 38. Logue, J. *et al.* (2011) Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia* 54, 3003–3006
 39. Petersen, M.C. *et al.* (2024) Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. *Cell Metab.* 36, 745–761.e5
 40. Schulze, M.B. and Stefan, N. (2024) Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. *Nat. Rev. Endocrinol.* 20, 633–646
 41. Smith, G.I. *et al.* Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics. *J. Clin. Invest.* 130, 3305–3314
 42. Mittendorfer, B. *et al.* β Cell function and plasma insulin clearance in people with obesity and different glycemic status. *J. Clin. Invest.* 132, e154068
 43. van Vliet, S. *et al.* (2020) Obesity is associated with increased basal and postprandial β -cell insulin secretion even in the absence of insulin resistance. *Diabetes* 69, 2112–2119
 44. Umpierrez, G.E. *et al.* (2006) Narrative review: ketosis-prone type 2 diabetes mellitus. *Ann. Intern. Med.* 144, 350–357
 45. Ohn, J.H. *et al.* (2016) 10-Year trajectory of β -cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. *Lancet Diabetes Endocrinol.* 4, 27–34
 46. Petersen, K.F. *et al.* (2006) Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. *Proc. Natl. Acad. Sci. U. S. A.* 103, 18273–18277
 47. Petersen, K.F. *et al.* (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 104, 12587–12594
 48. Birkenfeld, A.L. and Shulman, G.I. (2014) Non alcoholic fatty liver disease, hepatic insulin resistance and type 2 diabetes. *Hepatology* 59, 713–723
 49. Szendroedi, J. and Roden, M. (2009) Ectopic lipids and organ function. *Curr. Opin. Lipidol.* 20, 50
 50. Perry, R.J. *et al.* (2015) Hepatic acetyl coA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. *Cell* 160, 745–758
 51. Sancar, G. and Birkenfeld, A.L. (2024) The role of adipose tissue dysfunction in hepatic insulin resistance and T2D. *J. Endocrinol.* 262, e240115
 52. Roden, M. and Shulman, G.I. (2019) The integrative biology of type 2 diabetes. *Nature* 576, 51–61
 53. Robbins, A.L. and Savage, D.B. (2015) The genetics of lipid storage and human lipodystrophies. *Trends Mol. Med.* 21, 433–438
 54. Scott, R.A. *et al.* (2014) Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. *Diabetes* 63, 4378–4387
 55. Perry, R.J. *et al.* (2014) The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. *Nature* 510, 84–91
 56. Shulman, G.I. (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N. Engl. J. Med.* 371, 1131–1141
 57. Rytka, J.M. *et al.* (2010) The portal theory supported by venous drainage-selective fat transplantation. *Diabetes* 60, 56–63
 58. Bergman, M. (2013) Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. *Endocrine* 43, 504–513
 59. Taylor, R. (2008) Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. *Diabetologia* 51, 1781–1789
 60. Gerst, F. *et al.* (2017) Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion. *Diabetologia* 60, 2240–2251
 61. Gerst, F. *et al.* (2020) Glucose responsiveness of β -cells depends on fatty acids. *Exp. Clin. Endocrinol. Diabetes* 128, 644–653
 62. Samuel, V.T. *et al.* (2010) Lipid-induced insulin resistance: unravelling the mechanism. *Lancet* 375, 2267–2277
 63. Petersen, K.F. *et al.* (2022) Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. *JCI Insight* 7, e157906
 64. Stefan, N. *et al.* (2008) Identification and characterization of metabolically benign obesity in humans. *Arch. Intern. Med.* 168, 1609–1616
 65. Stefan, N. *et al.* (2016) Phenotypes of prediabetes and stratification of cardiometabolic risk. *Lancet Diabetes Endocrinol.* 4, 789–798
 66. Yu, H. *et al.* (2022) Association of weight status and the risks of diabetes in adults: a systematic review and meta-analysis of prospective cohort studies. *Int. J. Obes.* 46, 1101–1113
 67. Tobias, D.K. *et al.* (2014) Body-mass index and mortality among adults with incident type 2 diabetes. *N. Engl. J. Med.* 370, 233–244
 68. Abdul-Ghani, M.A. *et al.* (2006) Contributions of β -cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. *Diabetes Care* 29, 1130–1139
 69. DeFronzo, R.A. *et al.* (1989) Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. *Metabolism* 38, 387–395
 70. Cherrington, A.D. (1999) Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. *Diabetes* 48, 1198–1214
 71. Petersen, M.C. *et al.* (2017) Regulation of hepatic glucose metabolism in health and disease. *Nat. Rev. Endocrinol.* 13, 572–587
 72. Ha, J. *et al.* (2023) One-hour glucose is an earlier marker of dysglycemia than two-hour glucose. *Diabetes Res. Clin. Pract.* 203, 110839
 73. Leahy, J.L. (2005) Pathogenesis of type 2 diabetes mellitus. *Arch. Med. Res.* 36, 197–209
 74. Weyer, C. *et al.* (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J. Clin. Invest.* 104, 787–794
 75. Sallar, A. and Dagogo-Jack, S. (2020) Regression from prediabetes to normal glucose regulation: state of the science. *Exp. Biol. Med. (Maywood)* 245, 889–896
 76. Owei, I. *et al.* (2017) Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident prediabetes in a longitudinal biracial cohort. *BMJ Open Diabetes Res. Care* 5, e000415
 77. James, D. *et al.* (2020) Multi-year reproducibility of hyperinsulinemic euglycemic clamp-derived insulin sensitivity in free-living adults: association with incident prediabetes in the POP-ABC study. *Metabolism* 109, 154263
 78. Dagogo-Jack, S. *et al.* (2014) Lack of racial disparity in incident prediabetes and glycemic progression among Black and White offspring of parents with type 2 diabetes: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. *J. Clin. Endocrinol. Metab.* 99, E1078–E1087
 79. Færch, K. *et al.* (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? *Diabetologia* 52, 1714–1723
 80. Nathan, D.M. *et al.* (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 30, 753–759
 81. Abdul-Ghani, M. *et al.* (2024) Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes. *Lancet Diabetes Endocrinol.* 12, 674–680
 82. Kanat, M. *et al.* (2011) Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. *Acta Diabetol.* 48, 209–217
 83. Åhrén, B. and Larsson, H. (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. *Diabetologia* 44, 1998–2003
 84. Abdul-Ghani, M. and DeFronzo, R.A. (2007) Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. *J. Clin. Endocrinol. Metab.* 92, 1778–1784
 85. Vollmer, K. *et al.* (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. *Diabetes* 57, 678–687

86. Færch, K. *et al.* (2009) Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. *Diabetes Care* 32, 439–444
87. Abdul-Ghani, M.A. *et al.* (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. *Diabetes* 55, 1430–1435
88. Festa, A. *et al.* (2004) Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. *Diabetes* 53, 1549–1555
89. Weyer, C. *et al.* (1999) Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. *Diabetes* 48, 2197–2203
90. Wasada, T. *et al.* (2004) Who are more insulin resistant, people with IFG or people with IGT? *Diabetologia* 47, 759–760
91. Shulman, G.I. *et al.* (1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by ¹³C nuclear magnetic resonance spectroscopy. *N. Engl. J. Med.* 322, 223–228
92. Cline, G.W. *et al.* (1999) Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. *N. Engl. J. Med.* 341, 240–246
93. Petersen, K.F. and Shulman, G.I. (2002) Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. *Am. J. Cardiol.* 90, 11–18
94. Fritsche, A. *et al.* (2000) Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. *Diabetologia* 43, 852–858
95. Michaliszyn, S.F. *et al.* (2014) β -Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. *Diabetes* 63, 3846–3855
96. Linder, K. *et al.* (2014) Maternal insulin sensitivity is associated with oral glucose-induced changes in fetal brain activity. *Diabetologia* 57, 1192–1198
97. Linder, K. *et al.* (2015) Gestational diabetes impairs human fetal postprandial brain activity. *J. Clin. Endocrinol. Metab.* 100, 4029–4036
98. Abdul-Ghani, M.A. *et al.* (2009) Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes. *Diabetes Care* 32, 281–286
99. Meyer, C. *et al.* (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. *Diabetes Care* 29, 1909–1914
100. Giráldez-García, C. *et al.* (2021) The heterogeneity of reversion to normoglycemia according to prediabetes type is not explained by lifestyle factors. *Sci. Rep.* 11, 9667
101. Tura, A. *et al.* (2021) Profiles of glucose metabolism in different prediabetes phenotypes, classified by fasting glycemia, 2-hour OGTT, glycated hemoglobin, and 1-hour OGTT: an IMI DIRECT study. *Diabetes* 70, 2092–2106
102. Carnevale Schianca, G.P. *et al.* (2003) The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. *Diabetes Care* 26, 1333–1337
103. Bergman, M. (2024) Prediabetes remission in people with obesity. *Lancet Diabetes Endocrinol.* 12, 603–605
104. Manco, M. *et al.* (2010) One-hour plasma glucose identifies insulin resistance and β -cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. *Diabetes Care* 33, 2090–2097
105. Bergman, M. *et al.* (2024) International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. *Diabetes Res. Clin. Pract.* 209, 111589
106. Cefalo, C.M.A. *et al.* (2024) Pathophysiological characteristics of subjects with intermediate hyperglycemia and type 2 diabetes identified by 1-hour plasma glucose during an oral glucose tolerance test. *Diabetes Res. Clin. Pract.* 217, 111856
107. Wagner, R. *et al.* (2021) Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. *Nat. Med.* 27, 49–57
108. Mutie, P.M. *et al.* (2020) An investigation of causal relationships between prediabetes and vascular complications. *Nat. Commun.* 11, 4592
109. Prystupa, K. *et al.* (2023) Clusters of prediabetes and type 2 diabetes stratify all-cause mortality in a cohort of participants undergoing invasive coronary diagnostics. *Cardiovasc. Diabetol.* 22, 211
110. Ramachandran, A. *et al.* (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* 49, 289–297
111. Lindström, J. *et al.* (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. *Lancet* 368, 1673–1679
112. Li, G. *et al.* (2014) Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. *Lancet Diabetes Endocrinol.* 2, 474–480
113. Zhang, L. *et al.* (2023) Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. *Lancet Diabetes Endocrinol.* 11, 567–577
114. Fritsche, A. *et al.* (2021) Different effects of lifestyle intervention in high- and low-risk prediabetes: results of the randomized controlled Prediabetes Lifestyle Intervention Study (PLIS). *Diabetes* 70, 2785–2795
115. Stefan, N. *et al.* (2015) A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. *Diabetologia* 58, 2877–2884
116. Wagner, R. *et al.* (2022) Lower hepatic fat is associated with improved insulin secretion in a high-risk prediabetes subphenotype during lifestyle intervention. *Diabetes* 72, 362–366
117. Adams, R. *et al.* (2016) Implementation of the YMCA diabetes prevention program throughout an integrated health system: a translational study. *Perm J.* 20, 15–241
118. Gruss, S.M. *et al.* (2019) Public health approaches to type 2 diabetes prevention: the US National Diabetes Prevention Program and beyond. *Curr. Diabetes Rep.* 19, 78
119. LeBlanc, E.S. *et al.* (2018) Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 320, 1172–1191
120. Jastreboff, A.M. *et al.* (2024) Tirzepatide for obesity treatment and diabetes prevention. *N. Engl. J. Med.*, Published online November 13, 2024. <https://doi.org/10.1056/NEJMoa2410819>
121. McGowan, B.M. *et al.* (2024) Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. *Lancet Diabetes Endocrinol.* 12, 631–642
122. Taylor, R. *et al.* (2023) Aetiology of type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis. *Clin. Sci.* 137, 1333–1346
123. Birkenfeld, A.L. and Mohan, V. (2024) Prediabetes remission for type 2 diabetes mellitus prevention. *Nat. Rev. Endocrinol.* 20, 441–442
124. Riddle, M.C. *et al.* (2021) Consensus report: definition and interpretation of remission in type 2 diabetes. *Diabetes Care* 44, 2438–2444
125. Taylor, R. *et al.* (2019) Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes Endocrinol.* 7, 726–736
126. Taylor, R. *et al.* (2018) Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. *Cell Metab.* 28, 547–556.e3
127. Sandforth, A. *et al.* (2023) Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). *Lancet Diabetes Endocrinol.* 11, 798–810

128. Jumpertz von Schwartzberg, R. *et al.* (2024) Role of weight loss-induced prediabetes remission in the prevention of type 2 diabetes: time to improve diabetes prevention. *Diabetologia* 67, 1714–1718
129. Main, S.K. *et al.* (2011) Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. *Diabetes Care* 35, 131–136
130. Wedell-Neergaard, A.-S. *et al.* (2019) Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: a randomized controlled trial. *Cell Metab.* 29, 844–855.e3
131. Taylor, R. (2021) Type 2 diabetes and remission: practical management guided by pathophysiology. *J. Intern. Med.* 289, 754–770
132. Kullmann, S. *et al.* (2020) Central nervous pathways of insulin action in the control of metabolism and food intake. *Lancet Diabetes Endocrinol.* 8, 524–534
133. Kullmann, S. *et al.* (2020) Brain insulin sensitivity is linked to adiposity and body fat distribution. *Nat. Commun.* 11, 1841
134. Kullmann, S. *et al.* (2021) Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial. *Diabetes Care* 45, 398–406
135. Kullmann, S. *et al.* Exercise restores brain insulin sensitivity in sedentary adults who are overweight and obese. *JCI Insight* 7, e161498
136. Campbell, M.D. *et al.* (2020) Benefit of lifestyle-based T2DM prevention is influenced by prediabetes phenotype. *Nat. Rev. Endocrinol.* 16, 395–400
137. Raverdy, V. *et al.* (2022) Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study. *Lancet Diabetes Endocrinol.* 10, 167–176
138. Prischl, F.C. *et al.* (2021) Major adverse renal events (MARE): a proposal to unify renal endpoints. *Nephrol. Dial. Transplant.* 36, 491–497
139. Perreault, L. *et al.* (2009) Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. *Diabetes Care* 32, 1583–1588
140. Vistisen, D. *et al.* (2019) Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study. *Diabetologia* 62, 1385–1390
141. Birkenfeld, A.L. *et al.* (2024) Precision medicine in people at risk for diabetes and atherosclerotic cardiovascular disease: a fresh perspective on prevention. *Circulation* 150, 1910–1912